Browse News
Filter News
Found 2,409 articles
-
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
3/27/2023
Vertex Pharmaceuticals Incorporated today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).
-
Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.
-
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
3/22/2023
Inozyme Pharma, Inc today reported financial results for the full year ended December 31, 2022, and provided recent business highlights.
-
Immatics Announces Full Year 2022 Financial Results and Corporate Update
3/21/2023
Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2022.
-
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema
3/21/2023
Intellia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to NTLA-2002 for the treatment of hereditary angioedema (HAE).
-
Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.
-
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
3/16/2023
Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
-
Synthego Introduces CRISPR Discovery Partners to Streamline CRISPR-Driven Drug Discovery Research
3/16/2023
Synthego Corp. announced the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services.
-
Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
3/16/2023
Seamless Therapeutics announced a $12.5 million seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform the treatment of severe diseases.
-
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
3/16/2023
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022.
-
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
3/15/2023
MaxCyte, Inc. announced its fourth quarter and full year ended December 31, 2022, financial results and provided initial 2023 revenue guidance.
-
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
3/15/2023
iOmx Therapeutics AG today announced that its high-throughput target discovery platform, myeloid iOTargTM, will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Molecular Assemblies Ships First Enzymatically Synthesized Oligonucleotides
3/14/2023
Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced it has shipped the first enzymatically synthesized oligonucleotides to top biotechnology, academic, and synthetic biology researchers, delivered as part of a key customer program.
-
Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy
3/14/2023
Vesigen Therapeutics, Inc. is pleased to announce receipt of a FARA General Research Grant. Vesigen will evaluate its proprietary technology to deliver CRISPR-Cas genome editing complexes as a non-viral disease-modifying strategy for patients diagnosed with the neurodegenerative disease Friedreich's Ataxia (FA).
-
Researchers study enhanced genetic animal model of Down syndrome
3/14/2023
National Institutes of Health researchers compared a new genetic animal model of Down syndrome to the standard model and found the updated version to be more similar to the changes seen in humans.
-
In Pivotal Demonstration, Epic Bio Accomplishes Persistent Gene Activation with Single Administration
3/14/2023
Epic Bio has presented new data demonstrating the achievement of persistent gene activation using its Gene Expression Modulation System (GEMS) platform.
-
DEM BioPharma Appoints Miriam Merad, M.D., Ph.D., to Scientific Advisory Board
3/14/2023
DEM BioPharma, Inc. today announced the addition of Miriam Merad, M.D., Ph.D., to its Scientific Advisory Board.
-
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
3/14/2023
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX) today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida.
-
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
3/14/2023
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place April 14 – 19, 2023, in Orlando, FL.
-
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.